RadNet, Inc. — FY2023 Form 10-K
Business context and period. This annual report covers the fiscal year ended December 31, 2023; it is not a standalone fourth-quarter report. RadNet operates outpatient imaging centers and related technology businesses. At year-end, it operated or managed 366 centers across seven U.S. states and reported Imaging Centers and Artificial Intelligence (AI) segments.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Total revenue | $1.617 billion | $1.430 billion |
| Income from operations | $98.7 million | $46.4 million |
| Operating margin | 6.1% | 3.2% |
| Net income | $30.3 million | $33.6 million |
| Net income attributable to RadNet common stockholders | $3.0 million; $0.05 diluted EPS | $10.7 million; $0.17 diluted EPS |
| Adjusted EBITDA, non-GAAP | $232.3 million | $192.5 million |
| Cash from operating activities | $220.9 million | $146.4 million |
| Cash and cash equivalents at year-end | $342.6 million | $127.8 million |
Revenue increased 13%; same-center Imaging Center revenue rose 6.8%, with same-center procedure volume up 5.7% and advanced MRI, PET and CT volumes up a combined 7.2%. Higher operating income reflected revenue growth and a $16.8 million gain on contributed imaging-center assets, partly offset by higher costs. Consolidated net income declined despite higher operating income, in part because 2023 included an $8.2 million non-cash loss on interest-rate swaps, versus a $39.6 million non-cash gain in 2022. Net income attributable to RadNet shareholders was also affected by earnings allocated to noncontrolling interests.
Cash used in investing activities was $201.5 million, including $176.6 million of property and equipment purchases. Financing activities provided $195.6 million, primarily reflecting net proceeds of $245.8 million from a June 2023 common-stock offering, offset partly by debt repayments. The offering increased shares outstanding and diluted existing shareholders.
At year-end, term-loan face value was $823.1 million; total debt obligations including equipment notes were about $840.1 million, with carrying value of approximately $830.0 million. No amounts were drawn on the Barclays or Truist revolvers; reported available capacity was $187.4 million and $50.0 million, respectively. Operating lease liabilities totaled $661.1 million. Management stated that available funding was adequate for the 12 months following year-end and longer term; the company reported compliance with credit-facility covenants.
Material changes, outlook and risks
- Imaging growth and cost pressures: Imaging Center revenue grew, but salaries and professional reading fees rose 10.5% and medical-supply costs rose 25.5%. Management cited staffing needs, a tight labor market, higher contrast-agent prices and greater isotope use.
- AI investment: AI segment revenue increased to $12.5 million from $4.4 million, while the segment recorded a $20.6 million net loss. Management expects AI losses to continue for several years. Aidence lung-related products required new FDA submissions and additional development work; the company recorded a $3.9 million impairment. Aidence milestone consideration was also reversed after the original regulatory milestones became unattainable under the agreement.
- Unusual items: RadNet recorded $5.1 million of lease-abandonment charges for two underutilized centers and the $16.8 million joint-venture contribution gain. Interest expense increased to $64.5 million from $50.8 million, reflecting higher borrowing balances and variable rates. The company received $14.5 million of cash payments under interest-rate swaps during 2023.
- Reimbursement and operating risks: CMS payment reductions for radiology services took effect January 1, 2024; management warned that further reimbursement cuts could pressure revenue and margins. Other key risks include labor-cost inflation, reliance on physician referrals and contracted radiology groups, capitation utilization risk, substantial debt and variable interest rates, healthcare-law compliance, and cybersecurity or operational disruption. California minimum-wage changes are expected to increase some costs in 2024.
- Outlook: The filing provides no clear numerical revenue or earnings guidance. Management expects positive operating cash flow and adequate liquidity, while noting capital needs and continued AI investment. In the first quarter of 2024, RadNet combined eRad with AI into a new Digital Health reporting segment, to be reflected retrospectively in later reports. A four-center California acquisition closed February 1, 2024.
Investor verification priorities
- Reconcile the improvement in operating income and Adjusted EBITDA with the decline in parent-attributable net income and diluted EPS; review noncontrolling-interest allocations and non-GAAP adjustments.
- Assess cash generation after capital expenditures, debt service and lease commitments, and confirm the terms and impact of the 2023 equity offering.
- Monitor variable-rate debt, hedge maturities and exposure to interest-rate increases; the filing estimates that a 1% rate rise would increase annual interest expense by about $4.2 million across specified term loans.
- Track the impact of 2024 Medicare reimbursement changes and wage inflation on procedure-level margins and cash flow.
- Verify the timing, regulatory status, commercial adoption and expected funding needs of AI products, including the consequences of the delayed Aidence FDA submission.
- Review the $16.8 million joint-venture gain, center utilization and closure actions, and the performance of joint ventures, whose equity earnings declined to $6.4 million from $10.4 million.
The independent auditor issued an unqualified opinion on the financial statements and internal controls; revenue recognition estimates were identified as a critical audit matter.